Filing summary
Identity and period: The supplied filing is AIkido Pharma Inc.’s Form 10-K for the fiscal year ended December 31, 2020, ticker AIKI—not a Dominari Holdings Inc. filing. The requested “2020 Q4” corresponds here to full-year reporting; quarterly figures are not provided.
Business context
AIkido describes itself as an early-stage biotechnology company developing preclinical oncology and antiviral candidates through university licenses and research partnerships. Its programs include DHA-dFdC for pancreatic cancer, KPC34 for AML/ALL, and a University of Maryland broad-spectrum antiviral platform. The filing reports no clinical-stage candidates and no biotechnology product revenue.
Financial results and liquidity
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $0 | $9,000 |
| Operating expenses | $6.546 million | $5.694 million |
| Loss from operations | $6.546 million | $5.685 million |
| Other expense (income), net | $5.791 million expense | $1.502 million income |
| Net loss | $12.337 million | $4.183 million |
| Net loss per share | $0.44 | $1.67 |
| Cash from operating activities | $(4.021) million | $(3.017) million |
At year-end, cash was $2.715 million and marketable securities were $24.801 million; current assets totaled $27.731 million. Total assets were $30.495 million, total liabilities $877,000, and stockholders’ equity $29.618 million. The balance sheet reports no debt. The company also held a $2.764 million investment in Hoth Therapeutics. Margins are not meaningful given negligible revenue and operating losses.
2020 financing activities provided $31.608 million, primarily from equity and warrant exercises. The company reported no contractual obligations. A February 2021 public offering raised approximately $86.2 million gross and $78.2 million net; management said available cash would fund operations for at least 12 months. The offering materially increased the share count.
Changes, outlook and risks
- Operating loss increased from $5.685 million to $6.546 million, while net loss rose substantially, largely reflecting the change in fair value of the Hoth investment: a $6.811 million loss in 2020 versus a $1.406 million gain in 2019. The Hoth holding’s reported fair value fell from $10.128 million to $2.764 million.
- Management planned 2021 formulation work and animal testing for DHA-dFdC, targeting intravenous and oral formulations by year-end and an eventual IND submission. The company had not submitted an IND or NDA as of the filing. Human testing in 2022 was described as a goal, not assured guidance.
- The UMB antiviral research agreement entails $3.1 million of milestone-related research payments over two years. The antiviral work remains early-stage; efficacy in humans is unproven.
- COVID-19 disrupted manufacturing and UMB research. Management said the pandemic’s specific financial impact could not be determined.
- Key risks include early-stage development and regulatory failure, reliance on third parties, need for additional capital, competition, uncertain commercialization and reimbursement, and stock-price volatility. The company was also evaluating strategic alternatives, without assurance of a transaction.
- Management concluded internal control over financial reporting and disclosure controls were ineffective at December 31, 2020, citing inadequate segregation of duties and insufficient controls to capture material transactions and developments. The auditor gave an unqualified opinion on the financial statements, but did not audit internal-control effectiveness.
Most important facts to verify
- Confirm issuer identity: this filing is for AIkido Pharma Inc. (AIKI), not Dominari Holdings Inc.
- Reconcile the MD&A discussion of operating loss and other expense with the audited statements; the filing’s narrative and tables should be checked against one another.
- Confirm the post-year-end offering’s gross and net proceeds and resulting dilution: the filing reports approximately $86.2 million gross and $78.2 million net, and 88.9 million shares outstanding as of March 25, 2021.
- Track actual progress, costs, and regulatory milestones for DHA-dFdC and the UMB antiviral program; all candidates were preclinical and timelines were aspirational.
- Monitor remediation of the disclosed material weaknesses in financial reporting controls and the company’s cash use relative to its stated runway.